A Propensity-Score Matched Analysis on Outcomes Using Recombinant Activated Factor VII in Pediatric Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia
Yinan LiFuxia Yan

Abstract

To evaluate the effect of recombinant activated factor VII (rFVIIa) administration on outcomes in pediatric cardiac surgery patients with postoperative bleeding. A propensity score-matched retrospective study. Single tertiary medical center. The study comprised 151 patients who received treatment with rFVIIa and were matched with control patients at a 1:2 ratio. None. The primary endpoints were thrombotic events, renal replacement therapy (RRT), and mortality. The secondary endpoints were length of intensive care unit stay and the reexploration rate. Patients in the rFVIIa group showed no significant differences in thrombotic events (odds ratio [OR] 1.03; 95% confidence interval [CI] 0.48-2.21; p = 0.948), mortality (OR 0.94; 95% CI 0.42-2.13; p = 0.891), and RRT (OR 1.38; 95% CI 0.73-2.58; p = 0.319). However, patients in the rFVIIa group experienced a prolonged length of intensive care unit stay (5.65 [3.00-12.28] d v 3.91 [1.83-6.77] d) and an increased reexploration rate (8.2% v 3.1%). High-dose rFVIIa was an independent risk factor of thrombotic events (OR 5.17; 95% CI 1.19-22.49; p = 0.029). This study found that rFVIIa is not associated with increased risks of postoperative thrombotic events, mortality, or RRT in pediatr...Continue Reading

Citations

Nov 20, 2020·Cardiology in the Young·Jessica ZinkZiyad M Binsalamah
Sep 5, 2021·Journal of Cardiothoracic and Vascular Anesthesia·Shannon MorrisonPaul Davies

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.